13 citations
,
August 2017 in “International Journal of Dermatology” This study reported that trichoscopy revealed distinctive patterns across different autoimmune bullous diseases, suggesting it can be a useful preliminary diagnostic tool for differentiating these conditions.
June 2024 in “The Journal of Dermatology” This letter to the editor addresses previously published work about risk factors of rituximab-induced thrombocytopenia in autoimmune bullous disease patients but presents no new research findings.
October 2022 in “JAAD international” This study found that more than 70% of patients with autoimmune blistering diseases experienced alopecia, with about 10% having scarring alopecia, and elevated Dsg1 ratios were linked to hair loss in pemphigus vulgaris.
88 citations
,
August 2019 in “Frontiers in immunology” This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.
1 citations
,
January 2025 in “Dermatologic Therapy” This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.
